mFOLFOX + FOLFIRI

mFOLFOX + FOLFIRI is a combination chemotherapy regimen used primarily in the treatment of advanced or metastatic colorectal cancer. It consists of two established regimens administered either sequentially or in an alternating fashion: - **mFOLFOX (modified FOLinic acid, Fluorouracil, OXaliplatin):** - Folinic acid (leucovorin): Enhances the cytotoxic effect of fluorouracil. - Fluorouracil (5-FU): An antimetabolite that inhibits DNA synthesis by incorporating into DNA and RNA. - Oxaliplatin: A platinum-based agent that causes DNA crosslinking and apoptosis. - **FOLFIRI (Folinic acid, Fluorouracil, IRInotecan):** - Folinic acid (leucovorin) - Fluorouracil (5-FU) - Irinotecan: A topoisomerase I inhibitor that prevents DNA replication. The mechanism of action involves targeting rapidly dividing cancer cells through multiple pathways—disruption of DNA synthesis/replication and enhancement of cytotoxicity. This combination is typically reserved for patients with metastatic colorectal cancer who require intensive systemic therapy[1][3][6]. The regimen may be used as part of first-line or subsequent lines depending on patient characteristics and prior treatments.

Other names

modified FOLFOX plus FOLFIRIsequential mFOLFOX and FOLFIRIalternating mFOLFOX/FOLFIRI